Allergan Given Average Recommendation of “Buy” by Analysts (NYSE:AGN)
Allergan (NYSE:AGN) has received a consensus rating of “Buy” from the twenty-three ratings firms that are currently covering the stock, Stock Ratings News reports. One investment analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $161.83.
A number of research firms have recently commented on AGN. Analysts at Leerink Swann upgraded shares of Allergan from a “market perform” rating to an “outperform” rating in a research note on Friday, August 8th. They now have a $184.00 price target on the stock. Separately, analysts at Zacks reiterated an “outperform” rating on shares of Allergan in a research note on Tuesday, July 22nd. They now have a $205.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Allergan in a research note on Tuesday, July 22nd. They now have a $200.00 price target on the stock, up previously from $190.00.
Allergan (NYSE:AGN) opened at 162.11 on Friday. Allergan has a 52 week low of $86.95 and a 52 week high of $174.49. The stock has a 50-day moving average of $163.5 and a 200-day moving average of $150.9. The company has a market cap of $48.176 billion and a P/E ratio of 38.13.
Allergan (NYSE:AGN) last announced its earnings results on Monday, July 21st. The company reported $1.51 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.44 by $0.07. The company had revenue of $1.83 billion for the quarter, compared to the consensus estimate of $1.77 billion. During the same quarter in the prior year, the company posted $1.22 earnings per share. The company’s quarterly revenue was up 16.7% on a year-over-year basis. Analysts expect that Allergan will post $5.80 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Friday, September 5th. Investors of record on Friday, August 15th will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.12%. The ex-dividend date of this dividend is Wednesday, August 13th.
Allergan, Inc is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.
Receive News & Ratings for Allergan Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.